{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:42:45Z","timestamp":1791236565315,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"25","license":[{"start":{"date-parts":[[2015,10,12]],"date-time":"2015-10-12T00:00:00Z","timestamp":1444608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/onc.2015.391","type":"journal-article","created":{"date-parts":[[2015,10,12]],"date-time":"2015-10-12T10:15:05Z","timestamp":1444644905000},"page":"3303-3313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans"],"prefix":"10.1038","volume":"35","author":[{"given":"H","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Q O","family":"Al-Aidaroos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B C P","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J P","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Thura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,12]]},"reference":[{"key":"BFonc2015391_CR1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","volume":"127","author":"GP Gupta","year":"2006","unstructured":"Gupta GP, Massague J . Cancer metastasis: building a framework. Cell 2006; 127: 679\u2013695.","journal-title":"Cell"},{"key":"BFonc2015391_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2174\/187152007784111278","volume":"7","author":"FM Johnson","year":"2007","unstructured":"Johnson FM, Gallick GE . SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 2007; 7: 651\u2013659.","journal-title":"Anticancer Agents Med Chem"},{"key":"BFonc2015391_CR3","doi-asserted-by":"crossref","first-page":"8851","DOI":"10.18632\/oncotarget.3316","volume":"6","author":"W Liu","year":"2015","unstructured":"Liu W, Yue F, Zheng M, Merlot A, Bae DH, Huang M et al. The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. Oncotarget 2015; 6: 8851\u20138874.","journal-title":"Oncotarget"},{"key":"BFonc2015391_CR4","doi-asserted-by":"publisher","first-page":"e0117215","DOI":"10.1371\/journal.pone.0117215","volume":"10","author":"S Rao","year":"2015","unstructured":"Rao S, Larroque-Lombard AL, Peyrard L, Thauvin C, Rachid Z, Williams C et al. Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting. PLoS One 2015; 10: e0117215.","journal-title":"PLoS One"},{"key":"BFonc2015391_CR5","doi-asserted-by":"publisher","first-page":"865819","DOI":"10.1155\/2011\/865819","volume":"2011","author":"B Sen","year":"2011","unstructured":"Sen B, Johnson FM . Regulation of SRC family kinases in human cancers. J Signal Transduct 2011; 2011: 865819.","journal-title":"J Signal Transduct"},{"key":"BFonc2015391_CR6","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1038\/sj.onc.1203923","volume":"19","author":"JD Bjorge","year":"2000","unstructured":"Bjorge JD, Jakymiw A, Fujita DJ . Selected glimpses into the activation and function of Src kinase. Oncogene 2000; 19: 5620\u20135635.","journal-title":"Oncogene"},{"key":"BFonc2015391_CR7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1097-2765(00)80356-1","volume":"3","author":"W Xu","year":"1999","unstructured":"Xu W, Doshi A, Lei M, Eck MJ, Harrison SC . Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 1999; 3: 629\u2013638.","journal-title":"Mol Cell"},{"key":"BFonc2015391_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/5971","volume":"21","author":"RB Irby","year":"1999","unstructured":"Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999; 21: 187\u2013190.","journal-title":"Nat Genet"},{"key":"BFonc2015391_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S0165-4608(00)00226-0","volume":"121","author":"M Nilbert","year":"2000","unstructured":"Nilbert M, Fernebro E . Lack of activating c-SRC mutations at codon 531 in rectal cancer. Cancer Genet Cytogenet 2000; 121: 94\u201395.","journal-title":"Cancer Genet Cytogenet"},{"key":"BFonc2015391_CR10","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3748\/wjg.v11.i15.2351","volume":"11","author":"YX Tan","year":"2005","unstructured":"Tan YX, Wang HT, Zhang P, Yan ZH, Dai GL, Wu MC et al. C-src activating mutation analysis in Chinese patients with colorectal cancer. World J Gastroenterol 2005; 11: 2351\u20132353.","journal-title":"World J Gastroenterol"},{"key":"BFonc2015391_CR11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1006\/bbrc.1998.8763","volume":"247","author":"A Egeo","year":"1998","unstructured":"Egeo A, Mazzocco M, Arrigo P, Vidal-Taboada JM, Oliva R, Pirola B et al. Identification and characterization of a new human gene encoding a small protein with high homology to the proline-rich region of the SH3BGR gene. Biochem Biophys Res Commun 1998; 247: 302\u2013306.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2015391_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0378-1119(02)00602-9","volume":"291","author":"M Mazzocco","year":"2002","unstructured":"Mazzocco M, Maffei M, Egeo A, Vergano A, Arrigo P, Di Lisi R et al. The identification of a novel human homologue of the SH3 binding glutamic acid-rich (SH3BGR) gene establishes a new family of highly conserved small proteins related to Thioredoxin superfamily. Gene 2002; 291: 233\u2013239.","journal-title":"Gene"},{"key":"BFonc2015391_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/sj.onc.1209107","volume":"25","author":"SM Majid","year":"2006","unstructured":"Majid SM, Liss AS, You M, Bose HR . The suppression of SH3BGRL is important for v-Rel-mediated transformation. Oncogene 2006; 25: 756\u2013768.","journal-title":"Oncogene"},{"key":"BFonc2015391_CR14","first-page":"5497","volume":"59","author":"ES Berleth","year":"1999","unstructured":"Berleth ES, Nadadur S, Henn AD, Eppolito C, Shiojiri S, Gurtoo HL et al. Identification, characterization, and cloning of TIP-B1, a novel protein inhibitor of tumor necrosis factor-induced lysis. Cancer Res 1999; 59: 5497\u20135506.","journal-title":"Cancer Res"},{"key":"BFonc2015391_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0192-0561(00)00071-0","volume":"22","author":"ES Berleth","year":"2000","unstructured":"Berleth ES, Henn AD, Gurtoo HL, Wollman R, Alderfer JL, Mihich E et al. A novel tumor necrosis factor-alpha inhibitory protein, TIP-B1. Int J Immunopharmacol 2000; 22: 1137\u20131142.","journal-title":"Int J Immunopharmacol"},{"key":"BFonc2015391_CR16","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1096\/fj.00-0543fje","volume":"15","author":"AD Henn","year":"2001","unstructured":"Henn AD, Berleth ES, Mihich E, Ehrke MJ . Changes in cytosolic and membrane TNF inhibitory protein-B1 (TIP-B1) levels associated with protection from TNF-induced cytotoxicity. FASEB J 2001; 15: 1315\u20131317.","journal-title":"FASEB J"},{"key":"BFonc2015391_CR17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/415530a","volume":"415","author":"LJ van 't Veer","year":"2002","unstructured":"van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530\u2013536.","journal-title":"Nature"},{"key":"BFonc2015391_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1471-2164-6-37","volume":"6","author":"MC Abba","year":"2005","unstructured":"Abba MC, Hu Y, Sun H, Drake JA, Gaddis S, Baggerly K et al. Gene expression signature of estrogen receptor alpha status in breast cancer. BMC Genomics 2005; 6: 37.","journal-title":"BMC Genomics"},{"key":"BFonc2015391_CR19","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.1065817","volume":"294","author":"S Saha","year":"2001","unstructured":"Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C St, Croix B et al. A phosphatase associated with metastasis of colorectal cancer. Science 2001; 294: 1343\u20131346.","journal-title":"Science"},{"key":"BFonc2015391_CR20","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1158\/0008-5472.CAN-06-3598","volume":"67","author":"H Wang","year":"2007","unstructured":"Wang H, Quah SY, Dong JM, Manser E, Tang JP, Zeng Q . PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res 2007; 67: 2922\u20132926.","journal-title":"Cancer Res"},{"key":"BFonc2015391_CR21","first-page":"2716","volume":"63","author":"Q Zeng","year":"2003","unstructured":"Zeng Q, Dong JM, Guo K, Li J, Tan HX, Koh V et al. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res 2003; 63: 2716\u20132722.","journal-title":"Cancer Res"},{"key":"BFonc2015391_CR22","first-page":"Unit 19.2","volume":"Chapter 19","author":"M Elkin","year":"2001","unstructured":"Elkin M, Vlodavsky I . Tail vein assay of cancer metastasis. Curr Protoc Cell Biol 2001; Chapter 19: Unit 19.2.","journal-title":"Curr Protoc Cell Biol"},{"key":"BFonc2015391_CR23","first-page":"2142","volume":"40","author":"MG Brattain","year":"1980","unstructured":"Brattain MG, Strobel-Stevens J, Fine D, Webb M, Sarrif AM . Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res 1980; 40: 2142\u20132146.","journal-title":"Cancer Res"},{"key":"BFonc2015391_CR24","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.2174\/1381612033454126","volume":"9","author":"M Warmuth","year":"2003","unstructured":"Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N . SRC family kinases: potential targets for the treatment of human cancer and leukemia. Curr Pharm Des 2003; 9: 2043\u20132059.","journal-title":"Curr Pharm Des"},{"key":"BFonc2015391_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2005.08.055","volume":"337","author":"R Roskoski Jr","year":"2005","unstructured":"Roskoski R Jr . Signaling by Kit protein-tyrosine kinase\u2014the stem cell factor receptor. Biochem Biophys Res Commun 2005; 337: 1\u201313.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2015391_CR26","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cellsig.2006.12.003","volume":"19","author":"A Arcaro","year":"2007","unstructured":"Arcaro A, Aubert M, Espinosa del Hierro ME, Khanzada UK, Angelidou S, Tetley TD et al. Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling. Cell Signal 2007; 19: 1081\u20131092.","journal-title":"Cell Signal"},{"key":"BFonc2015391_CR27","doi-asserted-by":"publisher","first-page":"5623","DOI":"10.1128\/MCB.16.10.5623","volume":"16","author":"DD Schlaepfer","year":"1996","unstructured":"Schlaepfer DD, Hunter T . Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein-tyrosine kinases. Mol Cell Biol 1996; 16: 5623\u20135633.","journal-title":"Mol Cell Biol"},{"key":"BFonc2015391_CR28","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1096\/fasebj.9.9.7601337","volume":"9","author":"R Seger","year":"1995","unstructured":"Seger R, Krebs EG . The MAPK signaling cascade. FASEB J 1995; 9: 726\u2013735.","journal-title":"FASEB J"},{"key":"BFonc2015391_CR29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jhep.2010.12.013","volume":"54","author":"AC Piguet","year":"2011","unstructured":"Piguet AC, Dufour JF . PI(3)K\/PTEN\/AKT pathway. J Hepatol 2011; 54: 1317\u20131319.","journal-title":"J Hepatol"},{"key":"BFonc2015391_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.gde.2003.12.002","volume":"14","author":"DD Schlaepfer","year":"2004","unstructured":"Schlaepfer DD, Mitra SK . Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev 2004; 14: 92\u2013101.","journal-title":"Curr Opin Genet Dev"},{"key":"BFonc2015391_CR31","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ceb.2006.08.011","volume":"18","author":"SK Mitra","year":"2006","unstructured":"Mitra SK, Schlaepfer DD . Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006; 18: 516\u2013523.","journal-title":"Curr Opin Cell Biol"},{"key":"BFonc2015391_CR32","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1242\/jcs.045112","volume":"123","author":"MD Schaller","year":"2010","unstructured":"Schaller MD . Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci 2010; 123: 1007\u20131013.","journal-title":"J Cell Sci"},{"key":"BFonc2015391_CR33","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1038\/oncsis.2013.15","volume":"2","author":"S Garritano","year":"2013","unstructured":"Garritano S, Inga A, Gemignani F, Landi S . More targets, more pathways and more clues for mutant p53. Oncogenesis 2013; 2: e54.","journal-title":"Oncogenesis"},{"key":"BFonc2015391_CR34","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1101\/gad.190678.112","volume":"26","author":"WA Freed-Pastor","year":"2012","unstructured":"Freed-Pastor WA, Prives C . Mutant p53: one name, many proteins. Genes Dev 2012; 26: 1268\u20131286.","journal-title":"Genes Dev"},{"key":"BFonc2015391_CR35","first-page":"6788","volume":"60","author":"A Sigal","year":"2000","unstructured":"Sigal A, Rotter V . Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000; 60: 6788\u20136793.","journal-title":"Cancer Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/onc2015391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2015391","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2015391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:58:44Z","timestamp":1684472324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2015391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,12]]},"references-count":35,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["BFonc2015391"],"URL":"https:\/\/doi.org\/10.1038\/onc.2015.391","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,12]]},"assertion":[{"value":"13 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}